



Mithra announces shelf life extension for Myring™ to 36 months

- Shelf life extended from 24 to 36 months in Europe
- Competitive advantage in terms of optimizing the supply chain costs and convenience for distributors, pharmacists and patients

Liege, Belgium, 4 August 2020 – 7:30 CEST – Mithra (Euronext Brussels: MITRA), a company dedicated to Women's Health, today announces that the European Authorities have approved the extension in the shelf life of its vaginal contraceptive ring Myring™ from 24 to 36 months, allowing distributors to optimize their supply chain management.

In November 2019, Mithra announced the first approval of advantageous modifications to Myring™ labelling, extending the shelf life from 18 to 24 months, and eliminating the requirement for special storage conditions¹. Previously, Myring™ needed to be refrigerated before dispensing to the patient, at a temperature between 2 °C and 8 °C, similar to the originator product. This additional extension of the shelf life from 24 to 36 months further reduces the impact on transport and storage costs.

To date, Mithra has licensed Myring™ to industry leaders in 35 countries, including the three biggest worldwide markets. Myring™ is currently available in packages of one, three and recently six rings. The further shelf life extension to 36 months allows Mithra to consider packaging of larger quantities of rings, which would provide an even more convenient option for distributors, pharmacists and patients.

François Fornieri, CEO Mithra Women's Health, commented: *"We are very pleased that the European Authorities have approved an extended shelf life to 36 months for our contraceptive ring. In addition to the removal of the requirement for special temperature storage, and the recently available 6-pack format, this valuable shelf life extension provides Myring™ a clear advantage over competitor products."*

For more information, please contact:

Alexandra Deschner (IRO) : +32 490 58 35 23 - investorrelations@mithra.com

Carole Kousis (Press) : +32 4 349 28 22 - press@mithra.com

About Myring™

Myring™ (etonogestrel/ethinyl estradiol vaginal ring) is a non-biodegradable, flexible, transparent, combination contraceptive vaginal ring, with an outer diameter of 54 mm and a cross-sectional diameter of 4 mm. It is made of ethylene vinylacetate copolymers, and contains 11.7 mg etonogestrel and 2.7 mg ethinyl estradiol. When placed in the vagina, each ring releases, in line with the originator (Nuvaring®), on average 0.120 mg/day of etonogestrel

¹ [Press release Mithra, 2019-11-08](#)

and 0.015 mg/day of ethinyl estradiol over a three-week period of use. The ring is to remain in place continuously for three weeks. It is removed for a one-week break, during which a withdrawal bleed usually occurs. A new ring is inserted one week after the last ring was removed.

About Mithra

Mithra (Euronext: MITRA) is a Belgian biotech company dedicated to transforming Women's Health by offering new choices through innovation, with a particular focus on contraception and menopause. Mithra's goal is to develop products offering better efficacy, safety and convenience, meeting women's needs throughout their life span. Its three lead development candidates are built on Mithra's unique native estrogen platform, Estetrol (E4): Estelle®, a new era in oral contraception, PeriNesta®, the first complete oral treatment targeting perimenopause and Donesta®, the next-generation hormone therapy. Mithra also develops and manufactures complex therapeutics in the areas of contraception, menopause and hormone-dependent cancers. It offers partners a complete spectrum of research, development and specialist manufacturing at its technological platform Mithra CDMO. Active in more than 100 countries around the world, Mithra has an approximate headcount of 250 staff members and is headquartered in Liège, Belgium. www.mithra.com

Important information

The contents of this announcement include statements that are, or may be deemed to be, "forward-looking statements". These forward-looking statements can be identified by the use of forward-looking terminology, including the words "believes", "estimates," "anticipates", "expects", "intends", "may", "will", "plans", "continue", "ongoing", "potential", "predict", "project", "target", "seek" or "should", and include statements the Company makes concerning the intended results of its strategy. By their nature, forward-looking statements involve risks and uncertainties and readers are cautioned that any such forward-looking statements are not guarantees of future performance. The Company's actual results may differ materially from those predicted by the forward-looking statements. The Company undertakes no obligation to publicly update or revise forward-looking statements, except as may be required by law.



News
Alerts

Subscribe to our mailing list on investors.mithra.com to receive our press releases by email or follow us on our social media :

[Linkedin](#) • [Twitter](#) • [Facebook](#)